Developing new treatments for glioblastoma that resist standard therapies
Perivascular tissue models to overcome MGMT-mediated temozolomide resistance in glioblastoma
This study is looking at glioblastoma, a tough type of brain cancer, to find better treatments that can work even when a certain protein makes current drugs less effective, and they're creating special models to better understand how the cancer spreads and how new drugs might help patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Urbana-Champaign NIH-funded |
| Lab location | 1 site (Champaign, United States) |
| Project ID | NIH-11212145 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain cancer that often resists treatment with the drug temozolomide due to a protein called MGMT. The team aims to create advanced tissue models that mimic the tumor environment, allowing for a better understanding of how glioblastoma invades surrounding tissues and how it can resist treatment. By using innovative biomaterials and microfluidics, they will test new drug derivatives designed to work independently of MGMT, potentially leading to more effective therapies for patients. This approach seeks to overcome the limitations of current animal models that do not accurately represent the challenges faced in treating glioblastoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma, particularly those who have shown resistance to temozolomide treatment.
Not a fit: Patients with glioblastoma who are not eligible for experimental treatments or those who have not received prior temozolomide therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma patients who currently have limited options due to drug resistance.
How similar studies have performed: While there have been studies exploring glioblastoma treatments, this specific approach using engineered tissue models and novel drug derivatives is relatively novel and has not been extensively tested.
Where this research is happening
Champaign, United States
- University of Illinois at Urbana-Champaign — Champaign, United States (Active)
Researchers
- Principal investigator: Harley, Brendan a. — University of Illinois at Urbana-Champaign
- Study coordinator: Harley, Brendan a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.